• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利鲁唑治疗肌萎缩侧索硬化症的成本效益。意大利荟萃分析研究合作组及意大利药物观察站

Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.

作者信息

Messori A, Trippoli S, Becagli P, Zaccara G

机构信息

Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, Florence, Italy.

出版信息

Pharmacoeconomics. 1999 Aug;16(2):153-63. doi: 10.2165/00019053-199916020-00004.

DOI:10.2165/00019053-199916020-00004
PMID:10539396
Abstract

OBJECTIVE

In patients with amyotrophic lateral sclerosis, long term treatment with riluzole has been reported to improve survival or tracheostomy-free survival in comparison with placebo. We conducted a pharmacoeconomic analysis for estimating the cost per life-year gained using this drug.

DESIGN

This study was an incremental cost-effectiveness lifetime analysis.

SETTING

The clinical material was derived from 2 placebo-controlled randomised controlled trials comparing riluzole versus usual care without riluzole, which were identified through a literature search based on the IOWA and the Medline systems.

PATIENTS AND INTERVENTIONS

The study included 633 patients with amyotrophic lateral sclerosis. Patient-level information was retrieved from 313 patients treated with riluzole and 320 patients assigned to placebo. Survival after randomisation was compared between the 2 groups using standard statistics (log-rank test and Cox analysis), whereas the lifetime survival gain was estimated using Gompertz extrapolation. Cost data relative to the expenditure for healthcare resources were obtained from published information (using the US average wholesale price for the acquisition cost of riluzole). Sensitivity testing assessed the impact of different cost-of-illness assumptions for treated and untreated patients.

MAIN OUTCOME MEASURES AND RESULTS

Our primary analysis showed that treatment with riluzole significantly prolonged survival [death risk = 0.77; 95% confidence interval (CI): 0.62 to 0.96; p = 0.022]. The lifetime survival gain (including 3% annual discounting) was, on average, 2.3 months per patient, while the incremental cost was around $US12,000 per patient. Hence, the cost-effectiveness ratio of riluzole versus usual care without riluzole was $US62,609 per life-year gained (discounted dollars per discounted years; 95% CI: $US13,458 to $US205,714). The sensitivity analysis, considering different values of national cost for riluzole, suggested an interval for this parameter ranging from $US45,048 to $US62,609.

CONCLUSIONS

Our study indicates that in patients with amyotrophic lateral sclerosis, riluzole has an unfavourable cost-effectiveness ratio or, at best, a borderline pharmacoeconomic profile.

摘要

目的

据报道,与安慰剂相比,肌萎缩侧索硬化症患者长期使用利鲁唑可提高生存率或无气管切开生存率。我们进行了一项药物经济学分析,以估算使用该药物每获得一个生命年的成本。

设计

本研究为增量成本效益终身分析。

背景

临床资料来源于两项安慰剂对照随机对照试验,比较了利鲁唑与不使用利鲁唑的常规治疗,这些试验是通过基于爱荷华州和医学文献数据库系统的文献检索确定的。

患者和干预措施

该研究纳入了633例肌萎缩侧索硬化症患者。从313例接受利鲁唑治疗的患者和320例分配至安慰剂组的患者中获取患者层面的信息。使用标准统计学方法(对数秩检验和Cox分析)比较两组随机分组后的生存率,而使用Gompertz外推法估算终身生存获益。与医疗资源支出相关的成本数据来自已发表的信息(使用利鲁唑获取成本的美国平均批发价格)。敏感性测试评估了不同疾病成本假设对治疗和未治疗患者的影响。

主要结局指标和结果

我们的初步分析表明,利鲁唑治疗可显著延长生存期[死亡风险=0.77;95%置信区间(CI):0.62至0.96;p=0.022]。每位患者的终身生存获益(包括3%的年度贴现)平均为2.3个月,而增量成本约为每位患者12,000美元。因此,与不使用利鲁唑的常规治疗相比,利鲁唑的成本效益比为每获得一个生命年62,609美元(贴现美元/贴现年;95%CI:13,458美元至205,714美元)。敏感性分析考虑了利鲁唑的不同国家成本值,表明该参数的区间为45,048美元至62,609美元。

结论

我们的研究表明,在肌萎缩侧索硬化症患者中,利鲁唑的成本效益比不佳,或至多处于药物经济学临界状态。

相似文献

1
Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.利鲁唑治疗肌萎缩侧索硬化症的成本效益。意大利荟萃分析研究合作组及意大利药物观察站
Pharmacoeconomics. 1999 Aug;16(2):153-63. doi: 10.2165/00019053-199916020-00004.
2
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206.
3
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Cochrane Database Syst Rev. 2002(2):CD001447. doi: 10.1002/14651858.CD001447.
4
The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.利鲁唑治疗英国肌萎缩侧索硬化症的成本效用分析。
J Neurol Sci. 2001 Oct 15;191(1-2):95-102. doi: 10.1016/s0022-510x(01)00618-9.
5
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD001447. doi: 10.1002/14651858.CD001447.pub3.
6
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD001447. doi: 10.1002/14651858.CD001447.pub2.
7
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.利鲁唑治疗肌萎缩侧索硬化的剂量范围研究。肌萎缩侧索硬化/利鲁唑研究组II。
Lancet. 1996 May 25;347(9013):1425-31. doi: 10.1016/s0140-6736(96)91680-3.
8
Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.利鲁唑治疗肌萎缩侧索硬化症的成本效益分析。
Pharmacoeconomics. 1997 Nov;12(5):578-84. doi: 10.2165/00019053-199712050-00008.
9
A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.肌萎缩侧索硬化症的成本效益框架,应用于利鲁唑。
Value Health. 2020 Dec;23(12):1543-1551. doi: 10.1016/j.jval.2020.06.012. Epub 2020 Oct 9.
10
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Cochrane Database Syst Rev. 2000(2):CD001447. doi: 10.1002/14651858.CD001447.

引用本文的文献

1
Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis.肌萎缩侧索硬化症的氨己烯酸:系统评价和荟萃分析。
Neurol Sci. 2022 Feb;43(2):889-897. doi: 10.1007/s10072-022-05867-6. Epub 2022 Jan 7.
2
A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity.一种计算组合方法鉴定出一种超氧化物歧化酶1错误折叠、聚集和细胞毒性的蛋白质抑制剂。
J Biol Chem. 2017 Sep 22;292(38):15777-15788. doi: 10.1074/jbc.M117.789610. Epub 2017 Aug 2.
3
Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.

本文引用的文献

1
Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.利鲁唑治疗肌萎缩侧索硬化症的成本效益分析。
Pharmacoeconomics. 1997 Nov;12(5):578-84. doi: 10.2165/00019053-199712050-00008.
2
Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.药物经济学研究中的统计分析。当前问题与标准综述。
Pharmacoeconomics. 1996 Jun;9(6):506-16. doi: 10.2165/00019053-199609060-00005.
3
Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo.
运动神经元病的经济学研究:系统方法学综述
Pharmacoeconomics. 2017 Apr;35(4):397-413. doi: 10.1007/s40273-016-0478-9.
4
Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.使用个体患者数据荟萃分析进行成本效益分析时受限平均生存时间的差异:一项案例研究的证据
PLoS One. 2016 Mar 9;11(3):e0150032. doi: 10.1371/journal.pone.0150032. eCollection 2016.
5
Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study.肌萎缩侧索硬化症的死亡率、健康状况、社会和经济后果:一项全国对照研究。
J Neurol. 2013 Mar;260(3):785-93. doi: 10.1007/s00415-012-6706-0. Epub 2012 Oct 27.
6
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.普拉克索(KNS-760704)对肌萎缩侧索硬化症患者的影响。
Nat Med. 2011 Nov 20;17(12):1652-6. doi: 10.1038/nm.2579.
7
Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.肌萎缩侧索硬化症治疗的成本效益:文献综述
Pharmacoeconomics. 2002;20(6):367-87. doi: 10.2165/00019053-200220060-00002.
8
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.中高度非霍奇金淋巴瘤患者的生存情况:比较第三代化疗方案与CHOP方案的随机研究的荟萃分析
Br J Cancer. 2001 Feb 2;84(3):303-7. doi: 10.1054/bjoc.2000.1566.
Bone Marrow Transplant. 1999 Mar;23(5):489-95. doi: 10.1038/sj.bmt.1701600.
4
Assisted suicide and alternatives in amyotrophic lateral sclerosis.肌萎缩侧索硬化症中的协助自杀及替代方案。
N Engl J Med. 1998 Oct 1;339(14):987-9. doi: 10.1056/NEJM199810013391409.
5
Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide.肌萎缩侧索硬化症患者及其护理人员对协助自杀的态度。
N Engl J Med. 1998 Oct 1;339(14):967-73. doi: 10.1056/NEJM199810013391406.
6
Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies.干扰素治疗慢性粒细胞白血病的成本效益:四项临床研究分析
Ann Oncol. 1998 Apr;9(4):389-96. doi: 10.1023/a:1008212411489.
7
Second bone marrow transplantation in non-Hodgkin's lymphoma.非霍奇金淋巴瘤的二次骨髓移植
J Clin Oncol. 1998 Feb;16(2):804-6. doi: 10.1200/JCO.1998.16.2.804.
8
A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.干扰素作为高危切除性皮肤黑色素瘤辅助治疗的回顾性成本效益分析。
Eur J Cancer. 1997 Aug;33(9):1373-9. doi: 10.1016/s0959-8049(96)00413-3.
9
Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.高危黑色素瘤中α-2B干扰素获益的经济学分析:完整性、简单性与清晰度之间的权衡
Eur J Cancer. 1997 Aug;33(9):1345-6. doi: 10.1016/s0959-8049(97)00184-6.
10
Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED].利鲁唑治疗肌萎缩侧索硬化症的实践指南:美国神经病学学会质量标准小组委员会报告[已退休]
Neurology. 1997 Sep;49(3):657-9. doi: 10.1212/wnl.49.3.657.